GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » EBITDA Margin %

Arovella Therapeutics (FRA:E4NA) EBITDA Margin % : -40,033.33% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Arovella Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Arovella Therapeutics's EBITDA for the six months ended in Dec. 2023 was €-2.40 Mil. Arovella Therapeutics's Revenue for the six months ended in Dec. 2023 was €0.01 Mil. Therefore, Arovella Therapeutics's EBITDA margin for the quarter that ended in Dec. 2023 was -40,033.33%.


Arovella Therapeutics EBITDA Margin % Historical Data

The historical data trend for Arovella Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics EBITDA Margin % Chart

Arovella Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -666.62 -1,876.45 -1,698.16 -2,657.36 -2,292.06

Arovella Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14,713.33 -1,612.15 -826.45 -23,943.75 -40,033.33

Competitive Comparison of Arovella Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Arovella Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arovella Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Arovella Therapeutics's EBITDA Margin % falls into.



Arovella Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Arovella Therapeutics's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-5.776/0.252
=-2,292.06 %

Arovella Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-2.402/0.006
=-40,033.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arovella Therapeutics  (FRA:E4NA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Arovella Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Arovella Therapeutics (FRA:E4NA) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton, WA, AUS, 3053
Arovella Therapeutics Ltd is a biotechnology company focused on developing therapies to treat human diseases. Its two focus areas are oncology and conditions that impact the central nervous system. The company's principal activity is the pharmaceutical development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer.

Arovella Therapeutics (FRA:E4NA) Headlines

No Headlines